^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS exon 2 wild-type

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    11ms
    Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type
    |
    Mekinist (trametinib) • Vectibix (panitumumab)
    12ms
    CL1-95029-001: S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Jan 2025 --> Jun 2025
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021
    over1year
    S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Feb 2024 --> Jul 2024
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021
    over1year
    Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    Accurate pathological diagnosis is prognostically valuable. The histological features of enteroblastic differentiation, elevated serum AFP levels, and the expression of oncofetal proteins play an important role in the tumor diagnosis.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • SALL4 (Spalt Like Transcription Factor 4)
    |
    KRAS mutation • KRAS wild-type • KRAS G13 • KRAS exon 2 mutation • NRAS G13 • KRAS exon 2 wild-type
    almost2years
    S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, Institut de Recherches Internationales Servier | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021
    almost2years
    FIRE-4: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (clinicaltrials.gov)
    P3, N=673, Active, not recruiting, Ludwig-Maximilians - University of Munich
    Trial completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Stivarga (regorafenib) • irinotecan • leucovorin calcium
    almost2years
    CR-SEQUENCE: Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (clinicaltrials.gov)
    P3, N=419, Active, not recruiting, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    almost2years
    Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type
    |
    Mekinist (trametinib) • Vectibix (panitumumab)
    almost2years
    S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
    P1, N=41, Recruiting, Institut de Recherches Internationales Servier | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021
    2years
    FIRE-4: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (clinicaltrials.gov)
    P3, N=673, Active, not recruiting, Ludwig-Maximilians - University of Munich | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Nov 2023
    Enrollment closed • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Stivarga (regorafenib) • irinotecan • leucovorin calcium
    2years
    AIO-KRK-0116: FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (clinicaltrials.gov)
    P2, N=109, Active, not recruiting, Ludwig-Maximilians - University of Munich | Trial primary completion date: Nov 2022 --> Nov 2023
    Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    2years
    FIRE-6: FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, Ludwig-Maximilians - University of Munich | Trial primary completion date: Aug 2022 --> Nov 2023
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
    |
    KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • Bavencio (avelumab) • irinotecan • leucovorin calcium